ArticleBlood2008
Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: results of 2 phase 1 studies.
Article in Blood, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00005988 (A Phase I Open-Label, Safety Study of Haploidentical Bone Marrow Transplantation), which is not on this map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I Open-Label, Safety Study of Haploidentical Bone Marrow Transplantation (BMT) After Ex Vivo Treatment of Bone Marrow With Anti-B7.1 and Anti-B7.2 Antibodies
Who cites it
32 citing papers in PubMed.
- Adoptive T Cell Therapy Following Haploidentical Hematopoietic Stem Cell Transplantation.Frontiers in immunology · 2019Review
- Ex Vivo Generation of Donor Antigen-Specific Immunomodulatory Cells: A Comparison Study of Anti-CD80/86 mAbs and CTLA4-lg Costimulatory Blockade.Cell transplantation · 2018Article
- Infusion of Alloanergized Donor Lymphocytes after CD34-selected Haploidentical Myeloablative Hematopoietic Stem Cell Transplantation.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018Article
- FOXP3-Positive Regulatory T Cells and Kidney Allograft Tolerance.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2017Review
- CD28 BlockadeFrontiers in immunology · 2017Article
- Allospecific Tregs Expanded After Anergization Remain Suppressive in Inflammatory Conditions but Lack Expression of Gut-homing Molecules.Molecular therapy : the journal of the American Society of Gene Therapy · 2016Article
- "No donor"? Consider a haploidentical transplant.Blood reviews · 2015Review
- Preventing stem cell transplantation-associated viral infections using T-cell therapy.Immunotherapy · 2015Review
- Clinical Outlook for Type-1 and FOXP3(+) T Regulatory Cell-Based Therapy.Frontiers in immunology · 2015Review
- Haploidentical SCT: the mechanisms underlying the crossing of HLA barriers.Bone marrow transplantation · 2014Review
- Antiviral T-cell therapy.Immunological reviews · 2014Review
- Accelerating immune reconstitution after hematopoietic stem cell transplantation.Clinical & translational immunology · 2014Review
- Immunological Outcome in Haploidentical-HSC Transplanted Patients Treated with IL-10-Anergized Donor T Cells.Frontiers in immunology · 2014Article
- Strategies in haploidentical stem cell transplantation in adults.Turkish journal of haematology : official journal of Turkish Society of Haematology · 2013Review
- T-cell costimulatory blockade in organ transplantation.Cold Spring Harbor perspectives in medicine · 2013Review
- T cell depletion in paediatric stem cell transplantation.Clinical and experimental immunology · 2013Review
- Review
- Allogeneic hematopoietic stem cell transplantation in China: where we are and where to go.Journal of hematology & oncology · 2012Review
- Progress in haploidentical stem cell transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2012Review
- Costimulatory blockade with monoclonal antibodies to induce alloanergy in donor lymphocytes.International journal of hematology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
We report the outcomes of 24 patients with high-risk hematologic malignancies or bone marrow failure (BMF) who received haploidentical bone marrow transplantation (BMT) after ex vivo induction of alloantigen-specific anergy in donor T cells by allostimulation in the presence of costimulatory blockade. Ninety-five percent of evaluable patients engrafted and achieved full donor chimerism. Despite receiving a median T-cell dose of 29 x10(6)/kg, only 5 of 21 evaluable patients developed grade C (n = 4) or D (n = 1) acute graft-versus-host disease (GVHD), with only one attributable death. Twelve patients died from treatment-related mortality (TRM). Patients reconstituted T-cell subsets and immunoglobulin levels rapidly with evidence of in vivo expansion of pathogen-specific T cells in the early posttransplantation period. Five patients reactivated cytomegalovirus (CMV), only one of whom required extended antiviral treatment. No deaths were attributable to CMV or other viral infections. Only 1 of 12 evaluable patients developed chronic GVHD. Eight patients survive disease-free with normal performance scores (median follow-up, 7 years). Thus, despite significant early TRM, ex vivo alloanergization can support administration of large numbers of haploidentical donor T cells, resulting in rapid immune reconstitution with very few viral infections. Surviving patients have excellent performance status and a low rate of chronic GVHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.